全文获取类型
收费全文 | 149258篇 |
免费 | 31159篇 |
国内免费 | 2393篇 |
专业分类
耳鼻咽喉 | 5158篇 |
儿科学 | 5333篇 |
妇产科学 | 2428篇 |
基础医学 | 2886篇 |
口腔科学 | 1469篇 |
临床医学 | 26512篇 |
内科学 | 46871篇 |
皮肤病学 | 7415篇 |
神经病学 | 14627篇 |
特种医学 | 6343篇 |
外科学 | 40746篇 |
综合类 | 232篇 |
现状与发展 | 72篇 |
预防医学 | 6919篇 |
眼科学 | 3313篇 |
药学 | 866篇 |
中国医学 | 11篇 |
肿瘤学 | 11609篇 |
出版年
2024年 | 684篇 |
2023年 | 4778篇 |
2022年 | 1170篇 |
2021年 | 3036篇 |
2020年 | 5998篇 |
2019年 | 2114篇 |
2018年 | 7342篇 |
2017年 | 7297篇 |
2016年 | 8373篇 |
2015年 | 8361篇 |
2014年 | 15422篇 |
2013年 | 15536篇 |
2012年 | 5339篇 |
2011年 | 5350篇 |
2010年 | 10273篇 |
2009年 | 14180篇 |
2008年 | 5663篇 |
2007年 | 3896篇 |
2006年 | 6371篇 |
2005年 | 3664篇 |
2004年 | 2936篇 |
2003年 | 1923篇 |
2002年 | 2015篇 |
2001年 | 3783篇 |
2000年 | 2999篇 |
1999年 | 3193篇 |
1998年 | 3633篇 |
1997年 | 3451篇 |
1996年 | 3351篇 |
1995年 | 3201篇 |
1994年 | 1937篇 |
1993年 | 1557篇 |
1992年 | 1367篇 |
1991年 | 1402篇 |
1990年 | 1051篇 |
1989年 | 1172篇 |
1988年 | 1009篇 |
1987年 | 846篇 |
1986年 | 880篇 |
1985年 | 712篇 |
1984年 | 544篇 |
1983年 | 517篇 |
1982年 | 511篇 |
1981年 | 398篇 |
1980年 | 358篇 |
1979年 | 306篇 |
1978年 | 328篇 |
1977年 | 396篇 |
1975年 | 277篇 |
1972年 | 302篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
111.
112.
PURPOSE: The aim of this study is (1) to develop a new method of risk classification for clinically localized prostate cancer; (2) to examine it in terms of compatibility with existing data such as nomograms; and (3) to compare it with existing risk-grouping methods. MATERIAL AND METHODS: The new grading system introduced here consists of three factors. The first is a prostate-specific antigen (PSA) of 4.1-10.0 ng/ml (score 0), 10.1-20.0 ng/ml (score 1), and >20.0 ng/ml (score 2). The second is a Gleason score (GS) of 6 (score 0), 7 (score 1), and 8-10 (score 2). The third is T classifications (UICC 2002) of T1c-T2a (score 0), T2b-T2c (score 1), and T3a (score 2). The sum of the three scores was named Prostate Risk Index (PRIX). Then, the compatibility of PRIX with the Partin Table, Kattan Nomogram, and Roach's formula was examined. At the same time, PRIX was compared with D'Amico, the National Comprehensive Cancer Network (NCCN), and Seattle classifications. RESULTS: PRIX 0 corresponded to 1-2% of pathologic lymph node involvement (pLN+) according to the Partin Table; PRIX 1 to 3-4%; PRIX 2 to 7-10%; PRIX 3 to 14-18%; PRIX 4 to 24-29%; PRIX 5 to 32-37%; and PRIX 6 to 42%. PRIX well separated the risks with relatively narrow ranges of probability, while D'Amico, NCCN, and Seattle classifications generally gave wide ranges especially for high-risk groups, both in the Partin Table and Kattan Nomogram. Roach's formula sometimes overestimated the risk compared to the Partin Table. CONCLUSION: PRIX fully corresponded to the Partin Table in terms of pLN+, and corresponded to the other nomograms better than any existing risk-grouping method. PRIX may thus function as a prognostic factor or contribute to patient selection in clinically localized prostate cancer. 相似文献
113.
Four Chinese patients (2 boys, 2 girls), ages 4–9 years, who had episodes of perception error of body schema and objects are reported. The metamorphopsia, which had been named Alice in Wonderland syndrome, is the major presentation. All of them were proved to have acute Epstein-Barr virus infection, as documented by positive heterophil antibody test and/or positive IgM antibody to Epstein-Barr virus capsid antigen. The duration of the perception disorder ranged from 1 week to 3 months. We believe that any young child presenting with Alice in Wonderland syndrome should undergo examination for Epstein-Barr virus infection; complete recovery from the disorder can be expected. 相似文献
114.
115.
116.
117.
118.
F. Hampton Roy MD 《Annals of Ophthalmology》2006,38(1):35-38
A red eye is a cardinal sign of ocular inflammation. Most cases are benign and can be managed by the primary care provider.
The key is recognizing cases requiring ophthalmological consultation by differentiating between ciliary and conjunctival injection.
Ciliary injection indicates inflammation of the cornea, iris, or ciliary body, whereas conjunctival injection mainly affects
the posterior conjunctival blood vessels.
The author has stated that he does not have a significant financial interest or other relationship with any product manufacturer
or provider of services discussed in this article. The author also does not discuss the use of off-label products, which includes
unlabeled, unapproved, or investigative products or devices. 相似文献
119.
120.